



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Haji Akber Aisa,
✉ sunnymchaoran@126.com

[†]These authors have contributed equally to this work and share first authorship

RECEIVED 27 October 2025
ACCEPTED 28 October 2025
PUBLISHED 21 November 2025

CITATION
Wu Y, Wang B, Mao X, Chen W and Aisa HA (2025) Correction: Harmine derivative B-9-3 inhibits non-small cell lung cancer via the VEGFA/PI3K/AKT pathway.
Front. Pharmacol. 16:1701287.
doi: 10.3389/fphar.2025.1701287

COPYRIGHT
© 2025 Wu, Wang, Mao, Chen and Aisa. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Correction: Harmine derivative B-9-3 inhibits non-small cell lung cancer via the VEGFA/PI3K/AKT pathway

Yuche Wu^{1,2†}, Bing Wang^{3†}, Xuwen Mao^{4†}, Wei Chen² and Haji Akber Aisa^{1*}

¹Xinjiang Technical Institute of Physics and Chemistry Chinese Academy of Sciences, Urumqi, Xinjiang, China, ²Xinjiang Huashidan Pharmaceutical Co., Ltd., Urumqi, Xinjiang, China, ³The Fourth Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China, ⁴College of Pharmacy, Xinjiang Medical University, Urumqi, Xinjiang, China

KEYWORDS

harmine derivative B-9-3, non-small cell lung cancer, apoptosis, angiogenesis, VEGFA/PI3K/AKT

A Correction on

Harmine derivative B-9-3 inhibits non-small cell lung cancer via the VEGFA/PI3K/AKT pathway

by Wu Y, Wang B, Mao X, Chen W and Akber Aisa H (2025). *Front. Pharmacol.* 16:1526952. doi: 10.3389/fphar.2025.1526952

Affiliation 4 ‘Xinjiang Huashidan Pharmaceutical Co., Ltd., Urumqi, Xinjiang, China’ was renumbered as Affiliation 2.

Affiliation 2 was erroneously omitted for author Yuche Wu. The **conflict of interest statement** has been corrected to “Authors YW and WC were employed by Xinjiang Huashidan Pharmaceutical Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”

The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.